New diabetes clinical trial: Empa PASS on Urinary Tract Malignancies

Published on: March 13, 2018 at 09:30PM
Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: empagliflozin;   Drug: SGLT-2 inhibitors;   Drug: DPP-4 inhibitors
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Active, not recruiting
http://ift.tt/2Io3Gaq